Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc.

In part one of season two of MobiHealthNews’ Emerging Technologies series, Mark Zhang, acting assistant under secretary for ...

Economic realities: Pharma leadership is often conditioned for the "high-risk, high-reward" physics of pipeline assets. MedTech operates on iterative innovation and service-heavy models. Bridging ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...

Research on rare diagnoses and the development of precision medicine depend on patients being able to share their health data in a secure and ethical manner. The research study, published in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. No two people are the same. Precision medicine, sometimes ...

The cleanest case study of pharma and diagnostics operating as one strategic engine is Roche. Instead of treating diagnostics ...

Ancestry-specific biomarkers, such as POLB, could reshape diagnostic and prognostic approaches in head and neck cancer. New ...

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a ...

Editor's Note: This story was initially published May 21. It was updated June 7 with IPO pricing information. Three years after talks of an IPO surfaced, health tech company Tempus AI lit the fuse and ...

Cutting-edge “precision medicine” has great potential to advance the diagnosis, treatment and ultimate prevention of different forms of diabetes, an international coalition of scientists reports in a ...